NeuroOne Q3 FY2023 product revenue $630K, up from $32K; net loss $3.5M

NEUROONE MEDICAL TECHNOLOGIES Corp

2023-Q3 EPS reported -$0.52 revenue$1,210,661

Product revenue $630K in Q3 FY2023 vs $32K YoY; collaboration revenue $1.46M in 9M.
Net loss $3.5M in Q3 vs $2.8M prior year; cash $3.1M at June 30 vs $8.1M at Sept 30.
Evo sEEG limited launch completed; full launch with Zimmer Biomet expected Q4. OneRF 510(k) submitted June 8.
Closed public offering net $5.2M and ATM net $2.5M in July 2023; no debt.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NEUROONE MEDICAL TECHNOLOGIES Corp reported fiscal third quarter 2023 ended June 30, 2023 results: revenue Product revenue was $630,000 in the fiscal third quarter 2023, net income Net loss was $3.5 million for the fiscal third quarter 2023.

Period: fiscal third quarter 2023 ended June 30, 2023
Revenue: Product revenue was $630,000 in the fiscal third quarter 2023
Net income: Net loss was $3.5 million for the fiscal third quarter 2023
Result: reported results

Exact text from the filing

On August 14, 2023, NeuroOne Medical Technologies Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

NEUROONE MEDICAL TECHNOLOGIES Corp filing history →

Source: SEC EDGAR

accession 0001213900-23-067061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.